In therapies for B-cell malignancies such as non-Hodgkin lymphoma or B-acute lymphoblastic leukemia (B-ALL), the scFv are typically designed to target CD19, a surface marker consistently expressed throughout B-cell development (38). Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.